Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cody J Peer

Showing results (81-90 of 140) with videos related to

Pageof 14
Sort By:
Arthritis & Rheumatology (Hoboken, N.J.)|February 26, 2025
Sustained Interferon Signature Suppression With Anifrolumab in a Patient With STING-Associated Vasculopathy with Onset in Infancy Refractory to JAK Inhibitor and Dazukibart TherapySara Alehashemi, Bjoern Buehring, Adriana A de Jesus, et al.
Science Translational Medicine|May 10, 2023
Inhibition of p38α MAPK restores neuronal p38γ MAPK and ameliorates synaptic degeneration in a mouse model of DLB/PDMichiyo Iba, Changyoun Kim, Somin Kwon, et al.
Anti-Cancer Drugs|February 9, 2018
Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lungSanjeeve Balasubramaniam, Christophe E Redon, Cody J Peer, et al.
Clinical Genitourinary Cancer|April 25, 2020
Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide TreatmentRavi A Madan, Keith T Schmidt, Fatima Karzai, et al.
Pigment Cell & Melanoma Research|July 28, 2016
Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanomaBih-Rong Wei, Helen T Michael, Charles H C Halsey, et al.
The Oncologist|May 31, 2022
A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-EnzalutamideKeith T Schmidt, Fatima Karzai, Marijo Bilusic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2018
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate CancerRussell Z Szmulewitz, Cody J Peer, Abiola Ibraheem, et al.
Cancer Biology & Therapy|November 12, 2019
Botryllamide G is an ABCG2 inhibitor that improves lapatinib delivery in mouse brainJonathan D Strope, Cody J Peer, Tristan M Sissung, et al.
Cancer Medicine|October 8, 2022
Systemic immune changes accompany combination treatment with immunotoxin LMB-100 and nab-paclitaxelGuillaume Joe Pegna, Min-Jung Lee, Cody J Peer, et al.
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|February 3, 2026
Heat-activated intravenous liposomal doxorubicin combined with mitomycin C hyperthermic intravesical chemotherapy (HIVEC) for treatment of bladder cancerAndrew S Mikhail, Sandeep Gurram, Vladimir A Valera, et al.
Pageof 14

Showing results (81-90 of 140) with videos related to

Sort By:
Pageof 14
Arthritis & Rheumatology (Hoboken, N.J.)|February 26, 2025
Sustained Interferon Signature Suppression With Anifrolumab in a Patient With STING-Associated Vasculopathy with Onset in Infancy Refractory to JAK Inhibitor and Dazukibart TherapySara Alehashemi, Bjoern Buehring, Adriana A de Jesus, et al.
Science Translational Medicine|May 10, 2023
Inhibition of p38α MAPK restores neuronal p38γ MAPK and ameliorates synaptic degeneration in a mouse model of DLB/PDMichiyo Iba, Changyoun Kim, Somin Kwon, et al.
Anti-Cancer Drugs|February 9, 2018
Phase I trial of belinostat with cisplatin and etoposide in advanced solid tumors, with a focus on neuroendocrine and small cell cancers of the lungSanjeeve Balasubramaniam, Christophe E Redon, Cody J Peer, et al.
Clinical Genitourinary Cancer|April 25, 2020
Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide TreatmentRavi A Madan, Keith T Schmidt, Fatima Karzai, et al.
Pigment Cell & Melanoma Research|July 28, 2016
Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanomaBih-Rong Wei, Helen T Michael, Charles H C Halsey, et al.
The Oncologist|May 31, 2022
A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-EnzalutamideKeith T Schmidt, Fatima Karzai, Marijo Bilusic, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2018
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate CancerRussell Z Szmulewitz, Cody J Peer, Abiola Ibraheem, et al.
Cancer Biology & Therapy|November 12, 2019
Botryllamide G is an ABCG2 inhibitor that improves lapatinib delivery in mouse brainJonathan D Strope, Cody J Peer, Tristan M Sissung, et al.
Cancer Medicine|October 8, 2022
Systemic immune changes accompany combination treatment with immunotoxin LMB-100 and nab-paclitaxelGuillaume Joe Pegna, Min-Jung Lee, Cody J Peer, et al.
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|February 3, 2026
Heat-activated intravenous liposomal doxorubicin combined with mitomycin C hyperthermic intravesical chemotherapy (HIVEC) for treatment of bladder cancerAndrew S Mikhail, Sandeep Gurram, Vladimir A Valera, et al.
Pageof 14